1. Home
  2. IPWR vs OTLK Comparison

IPWR vs OTLK Comparison

Compare IPWR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ideal Power Inc.

IPWR

Ideal Power Inc.

N/A

Current Price

$3.35

Market Cap

39.9M

Sector

Industrials

ML Signal

N/A

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

N/A

Current Price

$0.44

Market Cap

38.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IPWR
OTLK
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
38.7M
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
IPWR
OTLK
Price
$3.35
$0.44
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$10.75
$3.83
AVG Volume (30 Days)
84.2K
1.2M
Earning Date
01-01-0001
06-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.91
EPS
N/A
N/A
Revenue
N/A
$8,146,123.00
Revenue This Year
N/A
$1,726.70
Revenue Next Year
$3,233.33
$80.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.62
$0.38
52 Week High
$6.90
$3.39

Technical Indicators

Market Signals
Indicator
IPWR
OTLK
Relative Strength Index (RSI) 46.04 42.93
Support Level $2.91 $0.39
Resistance Level $4.35 $0.46
Average True Range (ATR) 0.37 0.03
MACD 0.01 0.02
Stochastic Oscillator 43.73 72.70

Price Performance

Historical Comparison
IPWR
OTLK

About IPWR Ideal Power Inc.

Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: